Clinical Trial Update: An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

View source ↗

Summary

An open-label expanded-access trial of SAGE-547 for Super-Refractory Status Epilepticus is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Super-refractory Status Epilepticus

Drugs mentioned

• SAGE-547 (brexanolone)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Super-Refractory Status Epilepticus | Status: NO_LONGER_AVAILABLE